GlassScriptPhysician profile
Colleen Carr
NPI 1245717594
$1,470.43
in general payments reported to CMS, 2019-2025
12 companies · $143 in 2025
The $143 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $197 · 2023: $495 · 2024: $330 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.02 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $435.23 | 2021-2024 | Camzyos, Eliquis |
| Csl Behring | $211.50 | 2023-2025 | Kcentra |
| Abbvie INC. | $165.24 | 2021-2025 | |
| Pfizer INC. | $135.91 | 2023-2025 | |
| Atricure, INC. | $134.83 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.87 | 2021-2024 | Lifevest |
| Daiichi Sankyo INC. | $94.55 | 2023-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $80.03 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $44.12 | 2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.03 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $18.69 | 2022 | |
| Lilly USA, LLC | $16.43 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.